Transjugular intrahepatic portosystemic shunt placement for refractory ascites: A single-centre experience

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 12, 2012, Pages 1494-1500

  Lodato, Francesca ^a   Berzigotti, Annalisa ^a   Lisotti, Andrea ^a   Azzaroli, Francesco ^a   Mosconi, Cristina ^a   Giampalma, Emanuela ^a   Renzulli, Matteo ^a   Cappelli, Alberta ^a   Buonfiglioli, Federica ^a   Calvanese, Claudio ^a   Zoli, Marco ^a   Golfieri, Rita ^a   Mazzella, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ascites; Cirrhosis; HVPG; MELD; TIPS

Indexed keywords

BILIRUBIN; CREATININE; SODIUM;

ADULT; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN RESTRICTION; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; SURGICAL MORTALITY; SURVIVAL; SURVIVAL PREDICTION; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VENOUS PRESSURE;

AGED; AREA UNDER CURVE; ASCITES; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; END STAGE LIVER DISEASE; FEMALE; HUMANS; HYPERTENSION, PORTAL; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84869995998     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.703239     Document Type: Article

References (25)

1. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417.
2. Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-54.
3. Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133:825-34. (Pubitemid 47374134)
4. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005;41:386-400. (Pubitemid 40165385)
5. Chalasani N, Clark WS, Martin LG, Kamean J, Khan MA, Patel NH, Boyer TD. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 2000;118:138-44. (Pubitemid 30020381)
6. Membreno F, Baez AL, Pandula R, Walser E, Lau DT. Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed. J Gastroenterol Hepatol 2005;20:474-81. (Pubitemid 40469351)
7. Russo MW, Jacques PF, Mauro M, Odell P, Brown RS Jr. Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt. Liver Transpl 2002;8:271-7. (Pubitemid 34257210)
8. Yoon CJ, Chung JW, Park JH. Transjugular intrahepatic portosystemic shunt for acute variceal bleeding in patients with viral liver cirrhosis: predictors of early mortality. AJR Am J Roentgenol 2005;185:885-9.
9. Schepke M, Roth F, Fimmers R, Brensing KA, Sudhop T, Schild HH, Sauerbruch T. Comparison of MELD, Child- Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol 2003;98:1167-74. (Pubitemid 36733783)
10. Ferral H, Vasan R, Speeg KV, Serna S, Young C, Postoak DW, Wholey MH, McMahan CA. Evaluation of a model to predict poor survival in patients undergoing elective TIPS procedures. J Vasc Interv Radiol 2002;13:1103-8. (Pubitemid 35332895)
11. Jalan R, Elton RA, Redhead DN, Finlayson ND, Hayes PC. Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. J Hepatol 1995;23:123-8.
12. Patch D, Nikolopoulou V, McCormick A, Dick R, Armonis A, Wannamethee G, Burroughs A. Factors related to early mortality after transjugular intrahepatic portosystemic shunt for failed endoscopic therapy in acute variceal bleeding. J Hepatol 1998;28:454-60. (Pubitemid 28133550)
13. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-71. (Pubitemid 30169932)
14. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70. (Pubitemid 32119037)
15. Bureau C, Métivier S, D'Amico M, Péron JM, Otal P, Pagan JC, et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol 2011;54:901-7.
16. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-76. (Pubitemid 26012105)
17. Thalheimer U, Leandro G, Samonakis DN, Triantos CK, Senzolo M, Fung K, et al. TIPS for refractory ascites: a single-centre experience. J Gastroenterol 2009;44:1089-95.
18. Guy J, Somsouk M, Shiboski S, Kerlan R, Inadomi JM, Biggins SW. New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clin Gastroenterol Hepatol 2009;7:1236-40.
19. Schepke M, Roth F, Koch L, Heller J, Rabe C, Brensing KA, et al. Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting for the prevention of variceal rebleeding. Digestion 2003;67:146-53. (Pubitemid 36829080)
20. Protocollo aziendale uso appropriato di albumina. Available at http://intranet.aosp.bo.it/files/protAlbumina-0.pdf.
21. Darwish Murad S, Luong TK, Pattynama PM, Hansen BE, van Buuren HR, Janssen HL. Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome. Liver Int 2008;28:249-56. (Pubitemid 351209268)
22. Hernandez-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, García-Pagán JC. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 2004;40:1197-202. (Pubitemid 39425576)
23. Hausegger KA, Karnel F, Georgieva B, Tauss J, Portugaller H, Deutschmann H, Berghold A. Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft. J Vasc Interv Radiol 2004;15:239-48. (Pubitemid 38316445)
24. Barrio J, Ripoll C, Banares R, Echenagusia A, Catalina MV, Camúñez F, Simó G, Santos L. Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE- covered stent-grafts versus bare stents. Eur J Radiol 2005;55:120-4. (Pubitemid 40798497)
25. Gazzera C, Righi D, Valle F, Ottobrelli A, Grosso M, Gandini G. Fifteen years' experience with transjugular intrahepatic portosystemic shunt (TIPS) using bare stents: retrospective review of clinical and technical aspects. Radiol Med 2009;114:83-94.